SCHEMBL506350

SCHEMBL506350

ClCc1cccc2c1OCO2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EED O75530 3/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
KDM4C Q9H3R0 1/20 0.41
P2RX7 Q99572 1/20 0.40
FAAH O00519 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
MTNR1A P48039 4/20 0.39
TSHR P16473 2/20 0.39
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GSK3B P49841 1/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 1/20 0.38
MT-CO2 P00403 1/20 0.38
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2260648 0.86 MTNR1A (0.53) MTNR1AKDM4ELMNA
SCHEMBL1145761 0.79 EED (0.46) EEDABCG2KDM4CP2RX7FAAH
SCHEMBL6262492 0.79 EED (0.46) EEDABCG2KDM4CP2RX7FAAH
SCHEMBL300072 0.79 EED (0.46) EEDABCG2KDM4CP2RX7FAAH
SCHEMBL506237 0.79 EED (0.46) EEDABCG2KDM4CFAAHL3MBTL1
SCHEMBL25477727 0.79 EED (0.46) EEDABCG2KDM4CP2RX7FAAH
SCHEMBL700738 0.79 EED (0.46) EEDABCG2KDM4CP2RX7FAAH
SCHEMBL2168952 0.79 EED (0.46) EEDABCG2KDM4CP2RX7FAAH
SCHEMBL2602430 0.79 EED (0.46) EEDABCG2KDM4CFAAHMTNR1A
SCHEMBL1145758 0.79 EED (0.46) EEDABCG2KDM4CP2RX7FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288933-B1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUND FOR RES DEV (US) 2021-10-06 EP disclosed
EP-3288933-B1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUND FOR RES DEV (US) 2021-10-06 EP disclosed
US-10370328-B2 Oxindole compounds and pharmaceutical compositions thereof MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2019-08-06 US disclosed
US-10370328-B2 Oxindole compounds and pharmaceutical compositions thereof MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2019-08-06 US disclosed
US-20180134659-A1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 2018-05-17 US disclosed
US-20180134659-A1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 2018-05-17 US disclosed
US-20180134659-A1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 2018-05-17 US disclosed
WO-2016176420-A1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2016-11-03 WO disclosed
EP-1720836-B1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8580780-B2 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist ELI LILLY AND COMPANY (US) 2013-11-12 US disclosed
US-20040209875-A1 Nonsteroidal antiinflammatory agents SCHERIN AKTIENGESELLSCHAFT (DE) 2004-10-21 US disclosed
WO-2004058733-A1 NON-STEROIDAL ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-07-15 WO disclosed
US-5731321-A Endothelin receptor antagonists MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1998-03-24 US disclosed
US-5700807-A Endothelin receptor antagonists MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1997-12-23 US disclosed
CN-1155539-A Endothelin receptor antagonists MERCK PATENT GMBH (DE) 1997-07-30 CN disclosed
EP-0757039-A1 Endothelin receptor antagonists MERCK PATENT GmbH (DE) 1997-02-05 EP disclosed
EP-0755934-A1 Endothelin receptor antagonists MERCK PATENT GmbH (DE) 1997-01-29 EP disclosed
EP-0215492-B1 USE OF PERFLUOROPOLYETHER DERIVATIVES FOR PROTECTING BUILDING MATERIALS FROM ATMOSPHERICAL AGENTS AUSIMONT S.p.A. (IT) 1991-05-08 EP disclosed
US-4746550-A Use of perfluoropolyether derivatives for protecting stone materials from atmospheric agents AUSIMONT S.P.A. (IT) 1988-05-24 US disclosed
EP-0215492-A2 Use of perfluoropolyether derivatives for protecting building materials from atmospherical agents AUSIMONT S.p.A. (IT) 1987-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370328-B2 Oxindole compounds and pharmaceutical compositions thereof PARK7, OPRK1, COMT EED 2904/4885ABCG2 77/4885KDM4C 3202/4885
US-20180134659-A1 OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF PARK7, OPRK1, COMT EED 2904/4885ABCG2 77/4885KDM4C 3202/4885
US-20040209875-A1 Nonsteroidal antiinflammatory agents PTGS1, PTGER1, PTGES EED 4217/4885ABCG2 2419/4885KDM4C 4234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.